Table of Contents
1. Cardiovascular defense challenges at the basic, clinical, and population levels
Jason C. Kovacic, Jose M. Castellano, and Valentin Fuster 7. Plaque neovascularizationl defense mechanisms, betrayal, or a war in progress Pedro R. Moreno, Meeranani Purushothaman, and K-Raman Purushothaman
18. LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos Lina Badimon and Gemma Vilahur
33. Evolving role of molecular imaging for new understanding: targeting myofibroblasts to predict remodeling Hans J. de Haas, Susanne W. van den Borne, Hendrikus H. Boersma, Riemer H.J.A. Slart, Valentin Fuster, and Jagat Narula
42. Molecular targets in heart failure gene therapy: current controversies and translational perspectives Victor Kairouz, Larissa Lipskaia, Roger J. Hajjar, and Elie R. Chemaly
51. Engineered arterial models to correlate blood flow to tissue biological response Jordi Martorell, Pablo Santomá, José J. Molins, Andrés A. García-Granada, José A. Bea, Elazer R. Edelman, and Mercedes Balcells
57. A bird’s-eye view of cell therapy and tissue engineering for cardiac regeneration Carolina Soler-Botija, Juli R. Bagó, and Antoni Bayes-Genis
66. Umbilical cord blood for cardiovascular cell therapy: from promise to fact Santiago Roura, Josep-Maria Pujal, and Antoni Bayes-Genis
71. Heart repair: from natural mechanisms of cardiomyocyte production to the design of new cardiac therapies Silvia Martin-Puig, Valentín Fuster, and Miguel Torres
82. Energy metabolism plasticity enables stemness programs Clifford D.L. Folmes, Timothy J. Nelson, Petras P. Dzeja, and Andre Terzic
90. The future: therapy of myocardial protection David Sanz-Rosa, Jaime Garcia-Prieto, and Borja Ibanez
99. The links between complex coronary disease, cerebrobascular disease, and degenerative brain disease Jason C. Kovacic, Jose M. Castellano, and Valentin Fuster
106. Optimal lipid targets for the new era of cardiovascular prevention Vimal Ramjee, danny J. Eapen, and Laurence S. Sperling
115. Controversies in blood pressure goal guidelines and masked hypertension Robert A. Phillips
123. Evolving diagnostic and prognostic imaging of the various cardiomyopathies Javier Sanz
131. The evolving landscape of quality measurement for heart failure Ashley A. Fitzgerald, Larry A. Allen, and Frederick A. Masoudi
140. Atrial Fibrillation, Stock, and quality of life Jason S. Chinitz, Jose M. Castellano, Jason C. Kovacic, and Valentin Fuster
151. Transcatheter aortic valve implantation and cerebrovascular events: the current state of the art Brian G. Hynes and Josep Rodés-Cabau
164. Are we ignoring the dilated thoracic aortia? Jose M. Castellano, Jason C. Kovacic, Javier Sanz, and Valentin Fuster
175. Corrigendum